BioStock: SynAct Pharma advances trial with boosted funding
In the fourth quarter, SynAct Pharma focused on progressing its Phase IIb study, ADVANCE, evaluating resomelagon in newly diagnosed severe…
1,329€
10,47%
Echtzeit-Aktienkurs SYNACT PHARMA AB
Bid:
Ask:
Nachrichten zur SYNACT PHARMA AB Aktie
BioStock: New and larger shareholders back SynActs capital raise - CEO comments
SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary…
BioStock: SynAct Pharma moves forward with filing process
Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon’s effect.…
BioStock: SynAct Pharma’s CEO provides an update
SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for…
BioStock: Synact focuses on pushing forward rheumatoid arthritis project
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting…
Synact’s new CEO to BioStock: “I’m hitting the ground running”
On March 20, SynAct Pharma convened an Extraordinary General Meeting, resulting in a new composition of the Board of Directors.…